Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Zoetis Inc. (ZTS): Billionaire William Ackman’s Pershing Square Sells 6 Million Shares

A newly-amended 13D filing with the Securities and Exchange Commission revealed that billionaire William Ackman‘s Pershing Square has decreased its stake in Zoetis Inc. (NYSE:ZTS) to 18.9 million common shares, which amass 3.8% of the company’s total outstanding stock. Previously, Pershing Square held close to 25 million shares that accounted for 5.0% of Zoetis’ outstanding stock, as reported in a 13D filing in May.

Zoetis is a company that produces a variety of animal health medicines and vaccines, mainly for domestic animals. The company’s stock has gained 3.28% over the last 12 months. In its latest financial report for the first quarter of 2016, Zoetis disclosed earnings per share of $0.41, in-line with estimates, on revenue of $1.16 billion, which slightly topped estimates of $1.10 billion. At the beginning of June, Jefferies Group reiterated its ‘Buy’ rating on the stock and raised its price target on it to $58 from $57. On the other hand, Citigroup Inc. downgraded the stock to ‘Neutral’ from ‘Buy’, though it raised its price target on it to $50 from $46.

At the end of the first quarter, 48 investors in our database held long positions in Zoetis (NYSE:ZTS), compared to 54 hedge funds long the stock a quarter earlier. Among them, the biggest position was held by Pershing Square, while the second-biggest position was reported by Paul Marshall and Ian Wace’s Marshall Wace LLP, and was worth around $398.4 million. Other investors with similar bullishness contained William von Mueffling’s Cantillon Capital Management, Steve Cohen’s Point72 Asset Management, and Ryan Pedlow’s Two Creeks Capital Management.

Bill Ackman, Carl C. Icahn, William A. Ackman, Pershing Square Capital Management, Icahn Capital LP,

Investors who are no longer optimistic about investing in Zoetis (NYSE:ZTS) include Scott Ferguson’s Sachem Head Capital, which dumped the biggest position of all the hedgies watched by Insider Monkey, worth an estimated $201.3 million in stock. Ken Griffin’s Citadel Investment Group, also said goodbye to its Zoetis position, worth about $145.4 million.

You can access the original SEC filing by clicking here.

Follow Zoetis Inc. (NYSE:ZTS)
Trade (NYSE:ZTS) Now!

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Pershing Square Capital Management 18,891,304 18,891,304 18,891,304 3.8%
PS Management GP 18,891,304 18,891,304 18,891,304 3.8%
William A. Ackman 18,891,304 18,891,304 18,891,304 3.8%

Bill Ackman
Bill Ackman
Pershing Square

Page 1 of 7 – SEC Filing


Washington, D.C. 20549




(Rule 13d-101)



PURSUANT TO § 240.13d-2(a)

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

Under the Securities Exchange Act of 1934



Zoetis Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)


(CUSIP Number)

Stephen Fraidin, Esq.

Steve Milankov, Esq.

Pershing Square Capital Management, L.P.

888 Seventh Avenue, 42nd Floor

New York, New York 10019

(212) 813-3700

With a
copy to:

Alan Sinsheimer, Esq.

Sullivan & Cromwell LLP

125 Broad Street

York, New York 10004

(212) 558-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 7, 2016

(Date of
Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which
is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for
other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not
be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Zoetis Inc. (NYSE:ZTS)
Trade (NYSE:ZTS) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.